Name: Emily Pratt Slatin
Pronouns: She/Her/Hers
Gender Identity: Female
Sexual Orientation: Lesbian
Legal Sex: Female
Genetic Sex: 46,XX
Condition: Intersex — XX Male Syndrome (SRY-positive), Partial Androgen Insensitivity, Ovotesticular DSD
Overview
Emily Slatin is a genetically female (46,XX) individual born with an intersex condition characterized by the presence of the SRY gene, which translocated to one of her X chromosomes. This led to the development of ovotesticular gonads and partial masculinization in utero. Due to partial androgen insensitivity, her body responded poorly to endogenous testosterone, resulting in a female phenotype with some atypical genital characteristics. She presents as female, was assigned female at birth, and has always identified as such.
Detailed Genetic and Endocrine Background
- Karyotype: 46,XX
- SRY Gene: Present
- Androgen Sensitivity: Partial insensitivity strongly suspected
- Phenotype: Female with ambiguous genitalia—small, phallic structure and flattened scrotal tissue
- Internal Anatomy:
- Ovotesticular tissue present
- Underdeveloped uterine and Müllerian structures confirmed
- History of blood in urine during menstrual cycles, indicative of endometrial tissue connecting to the urogenital tract
- Puberty:
- Feminization occurred spontaneously
- Intermittent blood in urine during teen years, concurrent with menstrual timing
- No typical menstruation or vaginal bleeding
- Breast development and lack of body hair typical of androgen-dominant puberty
- Hormones:
- Elevated LH/FSH, low-normal estradiol, and male-range testosterone
- Inadequate virilization despite hormone levels—hallmark of partial androgen receptor dysfunction
- Hormones currently in normal cisgender female range with prescribed supplemental hormones
- Fertility: Absent
- Diagnosis: XX Male Syndrome with Partial Androgen Insensitivity and Ovotesticular Disorder of Sex Development
Gender Identity and History
Emily has lived as female her entire life, both socially and psychologically. She has no history of gender confusion or re-assignment. A pediatrician affirmed her identity at age 8. At 16, she was formally diagnosed as intersex after clinical investigation revealed ovotestes, ambiguous genitalia, and underdeveloped uterine tissue. She was assigned female at birth, and her identity has remained consistent throughout her life.
HRT and Sexual Orientation
Emily began hormone replacement therapy (estrogen-based) to support secondary sexual characteristics and bone health. Doctors incorrectly warned her that estrogen would alter her sexual orientation. It did not. She has always been exclusively attracted to women and transfeminine individuals, and HRT only strengthened her alignment with her identity and attraction.
Sexual and Social Identity
Emily identifies as:
- Female
- Intersex
- Lesbian
- Queer
- Hermaphrodite (in a reclaimed and classical sense, referencing her ovotesticular anatomy)
She has zero genital preferences and experiences attraction based solely on a partner’s identity as female or transfeminine. Her partners have always been fully supportive and accepting of her intersex status. She reports no dysphoria, only mild body-related anxiety rooted in childhood trauma and familial rejection.
Clinical Considerations
- Emily is legally and biologically female, and this identity is non-negotiable.
- Misgendering is both incorrect and harmful.
- She is not transgender and should not be subjected to trans-specific protocols.
- She has no need or desire for genital “normalization” or surgery unless medically necessary and on her terms.
- Blood in urine during menstrual cycles is a key diagnostic clue and should not be dismissed—it suggests functioning uterine/endometrial remnants.
- HRT monitoring, bone density screening, and tailored endocrine assessments are advised.
- Psychological care, if needed, should be trauma-informed and intersex-affirming.
